Skip to main content
Father's Day Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Data could move J&J's Talvey earlier in myeloma therapy

The MonumenTAL-3 trial showed 24-month progression-free survival of 81.3% with the triple regimen, supporting J&J’s filing for earlier use.

Summary by Pharmaphorum
Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

2 Articles

PharmaphorumPharmaphorum
Center

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

Read Full Article
biopharmadive.combiopharmadive.com
Center

J&J multiple myeloma drug gains edge in earlier stage disease

The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news on Monday, June 15, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Johnson & Johnson icon

Johnson & Johnson

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal